特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
661000

世界の肝臓癌治療薬市場 - 成長、動向、予測

Liver Cancer Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 115 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
世界の肝臓癌治療薬市場 - 成長、動向、予測
出版日: 2019年04月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 115 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の肝臓癌治療薬市場は、2018年から2023年の予測期間中に、約8%のCAGRで成長する見通しです。癌治療の需要が高まる中、北米が市場を席捲しています。

当レポートでは、世界の肝臓癌治療薬市場を調査し、全体的な市場動向、製品・地域別の詳細動向、市場成長への影響要因の分析、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な推論

第5章 市場の概要

  • 現在の市場シナリオ
  • ポーターのファイブフォース分析
    • サプライヤーの交渉力
    • 消費者の交渉力
    • 新規参入の脅威
    • 代替製品とサービスの脅威
    • 業界内での競争

第6章 成長要因、阻害要因、機会と挑戦分析(DROC)

  • 市場の成長要因
    • 癌の発生率上昇
    • 高いアンメット医療ニーズ
    • その他
  • 市場の阻害要因
    • 薬物の有害作用
    • 低い患者アドヒアランス
    • 治療法に対する厳しい規制政策
    • その他
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 治療法別
    • 肝細胞癌
    • 胆管細胞癌
    • 肝芽腫
    • 標的療法
  • エンドユーザー別
    • 小児科
    • 大人
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • M&A分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Alnylam Pharmaceuticals Inc.
  • Onyx Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • ArQule Inc.
  • Jennerex Biotherapeutics Inc.
  • Celsion Corp.
  • Bayer Schering Pharma AG
  • 4SC AG
  • Bristol-Myers Squibb Company など

第10章 市場の将来展望

目次
Product Code: 52622

Market Overview

The liver cancer therapeutics market is expected to register a CAGR of nearly 8.00% during the forecast period, 2019-2024. The major factors for the growth of the liver cancer therapeutics market include the rising prevalence of liver cancer, increasing R&D investments for the development of novel therapies, and government initiatives to increase cancer awareness.

  • The change in the current lifestyle has led to the exposure of a large amount of population to certain risk factors that contribute to liver cancer. The risk factors include hepatitis (caused by either the hepatitis B or hepatitis C virus), type 2 diabetes, metabolic disorders, and excess body weight, alcohol consumption, and tobacco smoking.
  • Liver cancer risk increases substantially with the increase in one's body mass index (BMI). More than half of the adult population in the United States falls under the category referred to as overweight. Moreover, the high demand for therapeutic drugs for liver cancer along with the above-mentioned factor creates wide opportunities for the manufacturers to produce more drugs and thereby, create a competitive landscape.
  • The American Cancer Society had stated that there would be 29,000 cases of cancer death in the United States in 2017. Liver cancer incidence has been rising in the United States since the mid-1970s, and is expected to continue to grow until 2030.
  • Thus, owing to the increasing prevalence of liver cancer, the market is expected to witness a high CAGR over the forecast period.

Scope of the Report

Liver cancer is cancer that begins in the liver cells and the therapies used in the treatment of liver cancer are covered under this report. The market is segmented by type, therapy, and geography.

Key Market Trends

Hepatocellular Carcinoma is the Segment by Type is expected to be the Fastest Growing Segment

Hepatocellular carcinoma (HCC) is the most common form of liver cancer, which mostly occurs in people suffering from chronic liver diseases, like cirrhosis. Hepatocellular carcinoma is one of the major causes leading to cancer-related deaths worldwide. It is observed that the Asian and African countries have higher incidence rates of hepatocellular carcinoma than the developed world, due to the disparity in the major risk factors causing hepatocellular carcinoma, such as hepatitis C virus (HCV) and hepatitis B virus (HBV) infection in those regions. As per the data published by the National Organization for Rare Diseases (NORD), there are approximately six new cases of HCC per every 100,000 people in the general population of the United States. With the increase in the incidence of hepatocellular carcinoma, there is expected to be a huge demand for the liver cancer therapeutics. Hence, the rising incidence of cancer and high unmet medical needs are the major factors that drive the market in the forecast period.

North America is Expected to Dominate the Market

North America is expected to dominate the market, due to the presence of better healthcare infrastructure and rising geriatric population. According to the estimates of American Society of Clinical Oncology, there are 42,220 adults who are diagnosed with liver cancer in the United States in 2018, (of which there are 30,610 men and 11,610 women). According to the Center for Disease Control and Prevention (CDC), 32,908 new cases of liver cancer were identified in 2015 in the United States, of which, the death toll was 25,760. It is observed that for every 100,000 people, 8 new liver cancer cases, and 7 deaths were registered. Hence, the incidence of liver cancer in the United States has increased during 2015-2018. This is leading to an increasing demand for liver cancer treatment, which, in turn, is driving the market in the forecast period.

Competitive Landscape

The market studied is a consolidated market, owing to the presence of a few major market players. Market players are focusing on R&D to bring innovative treatments for the treatment of liver cancer. Some of the market players are ArQule Inc., Bayer AG, Bristol-Myers Squibb Company, Celsion Corp., Eisai Inc., Exelixis Inc, F. Hoffmann-La Roche Ltd, and Merck & Co. Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Liver Cancer
    • 4.2.2 Increasing R&D investments for the development of novel therapies
    • 4.2.3 Government Initiatives to Increase the Cancer Awareness
  • 4.3 Market Restraints
    • 4.3.1 Side Effect associated with Medication
    • 4.3.2 Stringent regulatory Policies for Therapeutics
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Hepatocellular Carcinoma
    • 5.1.2 Cholangio Carcinoma
    • 5.1.3 Hepatoblastoma
    • 5.1.4 Other
  • 5.2 By Therapy
    • 5.2.1 Targeted Therapy
    • 5.2.2 Radiation Therapy
    • 5.2.3 Immunotherapy
    • 5.2.4 Chemotherapy
    • 5.2.5 Other
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 ArQule Inc.
    • 6.1.2 Bayer AG
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 Celsion Corp.
    • 6.1.5 Eisai Inc.
    • 6.1.6 Exelixis, Inc
    • 6.1.7 F. Hoffmann-La Roche Ltd
    • 6.1.8 Merck & Co., Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.